Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00696241
First received: June 10, 2008
Last updated: July 27, 2011
Last verified: July 2011
  Purpose

The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.


Condition Intervention Phase
Hypertension
Drug: Azilsartan medoxomil and olmesartan
Drug: Olmesartan
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.


Secondary Outcome Measures:
  • Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

  • Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

  • Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.

  • Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

  • Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

  • Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

  • Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

  • Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

  • Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

  • Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

  • Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

  • Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

  • Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

  • Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.


Enrollment: 1275
Study Start Date: June 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azilsartan Medoxomil 20 mg QD Drug: Azilsartan medoxomil and olmesartan
Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
Other Names:
  • TAK-491
  • Edarbi
Experimental: Azilsartan Medoxomil 40 mg QD Drug: Azilsartan medoxomil and olmesartan
Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
Other Names:
  • TAK-491
  • Edarbi
Experimental: Azilsartan Medoxomil 80 mg QD Drug: Azilsartan medoxomil and olmesartan
Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Other Names:
  • TAK-491
  • Edarbi
Active Comparator: Olmesartan 40 mg QD Drug: Olmesartan
Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Other Name: Benicar®
Placebo Comparator: Placebo QD Drug: Placebo
Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.

Detailed Description:

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker and this study is being conducted to evaluate the efficacy and safety of oral azilsartan medoxomil compared to placebo and olmesartan in subjects with essential hypertension.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 11 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting blood pressure and pulse, body height and weight, physical examinations and electrocardiograms. Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at 24 hour intervals.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Has essential hypertension (defined as sitting trough clinic systolic blood pressure between 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic blood pressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg at Day 1).
  2. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.
  4. The subject is willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit. If the subject is on amlodipine prior to screening, the subject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

  1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.
  2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.
  3. History of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
  4. Clinically significant cardiac conduction defects (eg, third degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrial flutter).
  5. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  6. Secondary hypertension of any etiology.
  7. Is noncompliant (less than 70% or greater than 130%) with study medication during Placebo Run-In Period.
  8. Severe renal dysfunction or disease (based on calculated creatinine clearance less than 30 mL/min/1.73 m2) at Screening.
  9. Known or suspected unilateral or bilateral renal artery stenosis.
  10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within the past 2 years.
  11. History of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those subjects with basal cell or stage I squamous cell carcinoma of the skin).
  12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greater than 8.0%) at Screening.
  13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal, active liver disease, or jaundice at Screening.
  14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal per the central laboratory) at Screening.
  15. Upper arm circumference less than 24 cm or greater than 42 cm.
  16. Works night (3rd) shift (defined as 11 PM to 7 AM).
  17. Currently participating in another investigational study or has participated in an investigational study within 30 days prior to Screening.
  18. Any other serious disease or condition at Screening (or Randomization) that would compromise subject safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.
  19. Randomized in a previous azilsartan medoxomil study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00696241

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
Huntsville, Alabama, United States
United States, Arizona
Mesa, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
Tempe, Arkansas, United States
United States, California
Beverly Hills, California, United States
Carmichael, California, United States
Fountain Valley, California, United States
Long Beach, California, United States
Los Gatos, California, United States
Orangevale, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Spring Valley, California, United States
Tustin, California, United States
Westlake Village, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
United States, Connecticut
Farmington, Connecticut, United States
United States, Florida
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
United States, Georgia
Augusta, Georgia, United States
Lawrenceville, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Melrose Park, Illinois, United States
Naperville, Illinois, United States
Round Lake Beach, Illinois, United States
United States, Indiana
Valparaiso, Indiana, United States
United States, Kansas
Wichita, Kansas, United States
United States, Kentucky
Erlanger, Kentucky, United States
Lexington, Kentucky, United States
United States, Maine
Auburn, Maine, United States
United States, Massachusetts
West Yarmouth, Massachusetts, United States
United States, Michigan
Benzonia, Michigan, United States
Chelsea, Michigan, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Trenton, New Jersey, United States
Wildwood Crest, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Brooklyn, New York, United States
Orangevale, New York, United States
Rochester, New York, United States
United States, North Carolina
Burlington, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Statesville, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Kettering, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
United States, Oklahoma
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Altoona, Pennsylvania, United States
Reading, Pennsylvania, United States
United States, South Carolina
Mt. Pleasant, South Carolina, United States
Simpsonville, South Carolina, United States
Taylors, South Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
New Tazewell, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
North Richland Hills, Texas, United States
San Antonio, Texas, United States
United States, Utah
Draper, Utah, United States
United States, Virginia
Burke, Virginia, United States
Norfolk, Virginia, United States
United States, Washington
Tacoma, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Argentina
Provincia de Buenos Aires, Argentina
Provincia de Cordoba, Argentina
Mexico
Aguascalientes,, Mexico
Mexico DF, Mexico
San Luis Potosi, Mexico
Sponsors and Collaborators
Takeda
Investigators
Study Director: VP Clinical Science Strategy Takeda
  More Information

Additional Information:
Publications:
Responsible Party: Sr. VP, Clinical Science, Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00696241     History of Changes
Other Study ID Numbers: 01-05-TL-491-008, U1111-1113-8905
Study First Received: June 10, 2008
Results First Received: March 24, 2011
Last Updated: July 27, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Essential Hypertension
Cardiovascular Disease
High Blood Pressure
Drug Therapy

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Olmesartan
Olmesartan medoxomil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014